Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -792.50K | -1.07M | -1.27M | 371.80K | -1.99M |
| Total Depreciation and Amortization | 27.00K | 46.50K | 54.10K | 61.80K | 44.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 544.40K | 869.60K | 869.50K | -1.04M | 1.03M |
| Change in Net Operating Assets | 180.20K | 80.30K | 156.50K | 102.10K | -579.00K |
| Cash from Operations | -41.10K | -77.70K | -186.40K | -505.60K | -1.50M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 67.70K | 45.70K | 45.70K | 18.70K | -- |
| Total Debt Repaid | -13.70K | -18.60K | -19.80K | -21.70K | -50.20K |
| Issuance of Common Stock | -- | -- | -- | 0.00 | 560.60K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -26.80K | -28.90K |
| Cash from Financing | 38.80K | 19.90K | 19.00K | -22.30K | 358.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.20K | -57.70K | -167.40K | -527.90K | -1.14M |